The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

ANIP

ANI Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Overall research band Weak
Quality Weak
Valuation Strong
Balance sheet Very weak
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. Its product portfolio includes injectables, softgel capsules, Cortrophin gel, ILUVIEN, and YUTIQ, as well as oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company supplies its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals generates revenue by selling these pharmaceutical products to its diverse customer base.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC8.9%Model input; read with the evidence status and period context.
Operating margin9.2%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years42.2%Model input; read with the evidence status and period context.
FCF margin17.1%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.